Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs-PFs for poorly healed postoperative wounds
NCT04538885Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Cytokines & Interferons, Stem Cell Therapies
01
Overview
Phase 1, randomised, open-label trial of mesenchymal stem cell-derived pleiotropic factor in wound dehiscence (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Wound healing time at 1 month and Wound healing rate at 1 month. Status: unknown.
02
Drugs
mesenchymal stem cell-derived pleiotropic factor
03
Conditions
wound dehiscence
Beyond the preview
Go deeper on NCT04538885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538885.